Zepbound (tirzepatide) works by activating two hormone receptors, GIP and GLP-1. Its FDA label says this lowers how many calories people eat, likely by affecting appetite, and also slows how fast the stomach empties. In the SURMOUNT-1 trial (NEJM, 2022), people on the 15 mg dose lost an average of 20.9% of their body weight over 72 weeks, against 3.1% on placebo. Here is the answer to "how does Zepbound work" in plain terms, with the label's own wording and the trial numbers.
By Alexandru Vieru | Independently researched | The mechanism and dosing on this page are from the Zepbound prescribing information on DailyMed (revised August 2026, read 21 October 2026); trial results are from the published papers. This is general information, not medical advice.
What Zepbound is
Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist, made by Eli Lilly. A once-weekly injection: single-dose pens and vials, and a multi-dose KwikPen.
Who it’s approved for
- Adults with obesity, or adults with overweight and at least one weight-related condition, to lose weight and keep it off, alongside a reduced-calorie diet and more physical activity.
- Adults with obesity and moderate to severe obstructive sleep apnea.
How it’s taken
- Once a week, injected under the skin.
Doses
- Starts at 2.5 mg a week for 4 weeks, then rises in 2.5 mg steps at least 4 weeks apart. Maintenance for weight is 5, 10 or 15 mg a week; for sleep apnea, 10 or 15 mg. The maximum is 15 mg a week.
Side effects
The most common, in 5% or more of people in its trials: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss and reflux.
The label also warns of severe stomach and bowel side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with insulin or sulfonylureas, diabetic eye complications and inhaling stomach contents under anesthesia. It can make birth control pills less effective: the label advises a non-oral method or a backup method for 4 weeks after starting and after each dose increase.
Boxed warning. Risk of thyroid C-cell tumors: tirzepatide causes these tumors in rats, and it is unknown whether it does in humans. Zepbound must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
From the FDA prescribing information for Zepbound (revised August 2026), read on DailyMed on 16 October 2026. A summary, not medical advice: a clinician decides whether it suits you.
How does Zepbound work in the body?
The label's mechanism section is short. It says: "Tirzepatide is a GIP receptor and GLP-1 receptor agonist." An agonist is a molecule that switches a receptor on. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are hormones the body makes itself; the label calls them "native GIP and GLP-1." Tirzepatide binds to and activates the receptors for both.
The label adds that tirzepatide "contains a C20 fatty diacid that enables albumin binding and prolongs the half-life." That fatty chain lets the drug ride on albumin, a protein in the blood, which keeps it in the body long enough for a once-weekly dose. The label puts the elimination half-life at about 5 to 6 days in people with overweight or obesity.
So the short answer to "how does Zepbound work" is: one weekly dose acts like two of the body's own appetite and blood sugar hormones at once.
What do GIP and GLP-1 do for appetite?
The label is careful about how much is known. On GLP-1 it says: "GLP-1 is a physiological regulator of appetite and caloric intake." On GIP it is more tentative: "Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake."
It also says that both receptor types "are found in areas of the brain involved in appetite regulation," and that animal studies show tirzepatide reaches and activates neurons in those regions.
In its pharmacodynamics section the label sums up the effect on weight:
- "Tirzepatide lowers body weight with greater fat mass loss than lean mass loss."
- "Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite."
- It stimulates insulin release only when blood sugar is raised (the label calls this "glucose-dependent"), reduces glucagon, and increases insulin sensitivity. Together these can lower blood sugar.
That appetite effect is the heart of the "how does Zepbound work" question. The label does not claim more than "likely mediated by affecting appetite," so neither do we.
Does Zepbound slow digestion?
Yes, and slower digestion is the second half of the answer to how does Zepbound work. The label says: "Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time." Food stays in the stomach longer, which is part of why early nausea is common.
Slower stomach emptying has two practical effects the label spells out:
- Birth control pills. Zepbound may make oral hormonal contraceptives less effective. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
- Surgery and sedation. The label warns of rare reports of people on GLP-1 medicines inhaling stomach contents under general anesthesia or deep sedation, and asks patients to tell their providers they take Zepbound before a procedure.
How much weight did people lose in SURMOUNT-1?
SURMOUNT-1 (NCT04184622) is one of the two weight-loss trials the Zepbound label relies on. The label calls it Study 1. SURMOUNT-1 was published in the New England Journal of Medicine on 4 June 2022 (print issue 21 July 2022), was supported by Eli Lilly, and tested brand tirzepatide for weight loss in adults without diabetes. In SURMOUNT-1, 2,539 adults with obesity, or with overweight and at least one weight-related condition, took tirzepatide 5 mg, 10 mg or 15 mg, or placebo, once a week for 72 weeks.
The label's results table for Study 1 at week 72 shows:
| Group (Study 1 on the label) | Average weight change | Lost 5% or more | Lost 10% or more | Lost 20% or more |
|---|---|---|---|---|
| Placebo | Down 3.1% | 34.5% | 18.8% | 3.1% |
| Zepbound 5 mg | Down 15.0% | 85.1% | 68.5% | 30.0% |
| Zepbound 10 mg | Down 19.5% | 88.9% | 78.1% | 50.1% |
| Zepbound 15 mg | Down 20.9% | 90.9% | 83.5% | 56.7% |
The published paper rounds the same results. In SURMOUNT-1, average weight fell by 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg at week 72, against 3.1% on placebo. In SURMOUNT-1, 85%, 89% and 91% of people on 5, 10 and 15 mg lost 5% or more of their body weight, against 35% on placebo. On 10 mg and 15 mg, 50% and 57% of SURMOUNT-1 participants lost 20% or more of their body weight, compared with 3% in the placebo group.
To put that in pounds: in SURMOUNT-1 the average starting weight was 104.8 kg, and 20.9% of that baseline is about 21.9 kg, or roughly 48 lb.
Those are averages, and everyone in the trial also received diet and activity counseling. The label notes that weight was missing at week 72 for 21.6% of the placebo group and 9.4% to 10.5% of the Zepbound groups, and the figures above fill those gaps with statistical imputation.
How long does it take Zepbound to work?
When people ask how does Zepbound work over time, there are two clocks: how fast the drug reaches your blood, and how fast weight changes.
- The drug itself. After an injection, the label gives a median time to peak blood level of 24 hours (range 8 to 72 hours). Steady levels are reached after 4 weeks of weekly doses.
- The dose. Zepbound starts at 2.5 mg and steps up by 2.5 mg no sooner than every 4 weeks, so reaching 15 mg takes at least 20 weeks.
- Weight. In the trials on the label, weight was measured after 72 weeks, including at least 52 weeks at the maintenance dose. The label shows the average weight curve as a figure, not as week-by-week numbers in its text.
The practical reading: the label says the slowing of stomach emptying is largest after the very first dose, while the weight results it reports were measured after 72 weeks of treatment. Progress is judged at the dose you stay on, not at the 2.5 mg starting dose.
Why does the Zepbound dose go up step by step?
The label explains the schedule in one line: the escalation is there "to reduce the risk of gastrointestinal adverse reactions." It also states that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." Maintenance for weight is 5, 10 or 15 mg a week.
The trial data match that reasoning. The label says "the majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time." In SURMOUNT-1, the most common side effects were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation.
Zepbound's own label has the full side effect table and dose chart, and your prescriber or pharmacist can show you where and how to inject each week.
What happens when you stop taking Zepbound?
SURMOUNT-4 tested this directly. In SURMOUNT-4, published in JAMA in January 2024, everyone first received the maximum tolerated dose of tirzepatide, 10 mg or 15 mg, for 36 weeks. Then, in SURMOUNT-4, 670 people were randomly assigned at week 36 to keep taking tirzepatide or switch to placebo for 52 weeks.
The results:
- In SURMOUNT-4, people had lost an average of 20.9% of their weight during the 36-week lead-in.
- From week 36 to week 88 in SURMOUNT-4, average weight went up by 14.0% for those switched to placebo, and went down by a further 5.5% for those who stayed on tirzepatide.
- At 88 weeks in SURMOUNT-4, 89.5% of people still on tirzepatide had kept at least 80% of the weight they lost in the lead-in, against 16.6% on placebo.
- Over the whole of SURMOUNT-4, from week 0 to week 88, average weight loss was 25.3% on tirzepatide and 9.9% for those switched to placebo.
The SURMOUNT-4 authors concluded that withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and added to the initial weight reduction. The label describes the same trial as Study 4. So for anyone asking how does Zepbound work in the long run, the trial answer is that it treats weight while you take it and does not reset it permanently. Any plan to stop or taper should be made with your prescriber.
How is Zepbound different from Mounjaro and semaglutide?
Mounjaro is the same medicine. Both are tirzepatide from Eli Lilly, with the same weekly doses; Mounjaro is approved for type 2 diabetes, and Zepbound for weight reduction and for obstructive sleep apnea in adults with obesity. The answer to how does Zepbound work is the same for Mounjaro.
Semaglutide (Wegovy and Ozempic) activates only the GLP-1 receptor. In SURMOUNT-5 (NEJM, 2025), the head-to-head trial, the least-squares mean weight change at 72 weeks was 20.2% lower with tirzepatide and 13.7% lower with semaglutide. Our semaglutide vs tirzepatide comparison covers the rest, and our tirzepatide guide covers prices and clinics.
How you get it does not change how it works. Lilly sells Zepbound vials and KwikPens to self-pay patients, and some online clinics, such as Shed (see our Shed review), list Zepbound among their prescriptions. For the routes and prices, read how to get Zepbound without insurance.
FAQ
How does Zepbound work for weight loss? It activates the GIP and GLP-1 receptors. The label says this decreases calorie intake, likely by affecting appetite, and that it delays stomach emptying.
Is Zepbound a GLP-1? It is a GLP-1 receptor agonist and also a GIP receptor agonist, which the label describes as "a GIP receptor and GLP-1 receptor agonist." Semaglutide acts on GLP-1 alone.
How quickly does Zepbound start working? Blood levels peak a median of 24 hours after an injection and become steady after 4 weeks of weekly doses. The weight results in the label were measured after 72 weeks.
Why do you start Zepbound at 2.5 mg? The label says the step-by-step increase is there to reduce stomach and bowel side effects, and that 2.5 mg is only a starting dose, not a maintenance dose.
Do you regain weight after stopping Zepbound? In SURMOUNT-4, people switched to placebo after 36 weeks regained weight: their average weight went up by 14.0% from week 36 to week 88, while those who stayed on tirzepatide lost a further 5.5%.
Does Zepbound work the same as Mounjaro? Yes. Both are tirzepatide made by Eli Lilly. They are approved for different conditions.
Sources
- Zepbound label on DailyMed, revised August 2026
- SURMOUNT-1, NEJM, 4 June 2022
- SURMOUNT-4, JAMA, 2 January 2024
- SURMOUNT-5, NEJM, 2025
Label read 21 October 2026.
Related reading
- Zepbound insurance coverage
- Semaglutide vs tirzepatide
- How to get Zepbound without insurance
- Tirzepatide: prices and clinics
- Zepbound side effects and dosage
- Where and how to inject Zepbound
- Does Zepbound need to be refrigerated?
- Zepbound and alcohol
- How long Zepbound stays in your system
